Author

A. Cherkasov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

N. A. Lack· 2 shared N. Lallous· 2 shared S. Lingadahalli· 2 shared A. Cingoz· 1 shared A. K. Parra-Nunez· 1 shared A. L.-F. Mui· 1 shared A. Ming-Lum· 1 shared A. Samiea· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

N. A. Lack

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex

S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, , N. A. Lack

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression.

F. Zhang, S. Wong, J. Lee, S. Lingadahalli, C. Wells, N. Saxena, C. Sanchez, B. Sun, A. K. Parra-Nunez, N. Chan, J. M. Bui, Y. Wang, P. S. Rennie, N. A. Lack, A. Cherkasov, , N. Lallous

This study shows that androgen receptor (AR) and its co-activator MED1 form dynamic, AR-rich condensates at superenhancers in prostate cancer, which are crucial for oncogenic gene expression.

bioRxiv · Mar 27, 2021Cancer Biology

Interleukin-10 and Small Molecule SHIP1 Allosteric Regulators Trigger Anti-Inflammatory Effects Through SHIP1/STAT3 Complexes

T. C. Chamberlain, S. T. Cheung, J. S. J. Yoon, A. Ming-Lum, B. R. Gill, S. Shakibakho, E. Dzananovic, F. Ban, A. Samiea, K. Jawanda, J. Priatel, G. Krystal, C. J. Ong, A. Cherkasov, R. J. Andersen, , A. L.-F. Mui

The paper shows IL10 induces a SHIP1/STAT3 complex in macrophages, and SHIP1 activators mimic IL10's anti-inflammatory effects in colitis.

bioRxiv · May 29, 2020Immunology

Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer Therapies

O. Snow, N. Lallous, M. Ester, A. Cherkasov

This study develops a deep neural network to predict Androgen Receptor mutant responses to prostate cancer therapies, showing improved accuracy over other machine learning methods.

bioRxiv · Jan 15, 2020Cancer Biology